Revium Rx (RVRC) Financiero

Revium Recovery, Inc. is a biotechnology company focused on the development of highly effective lipid-based therapies that redefine treatment standards. is a pre-clinical stage biopharmaceutical company. The company develops technologies and drug-delivery technological platforms. Its pipeline encompasses antibiotics for antimicrobial-resistant bacteria, immune checkpoint inhibitor adjuvant for solid tumors, and an immunization platform. The Company, through its subsidiary, LipoVation Ltd., develops a portfolio of NLP-based pharmaceutical candidates and plans to complete the development and commercialization of a series of medical technologies including: Nanoparticles-based formulation of a potent antibiotic which, based on in vitro and in vivo animal models studies, shows promising potential in combating severe life-threatening antibiotic-resistant bacteria (Nano-Mupirocin); Novel adjuvant to cancer therapies: a nanoparticles-based formulation of angiotensin receptor blockers for intravenous administration (Nano-Candesartan), and Liposomal Protein-Loaded Technology - an approach in immunization through nano particle-based vaccines.